Zactima Gets Fast Track Status for Medullary Thyroid Cancer

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS.

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.

Investigators are evaluating the efficacy and safety of APG-157 for patients with head and neck cancer in a phase 2 clinical trial.

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.